| Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018 |
393 |
| Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update |
57 |
| Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1. irRECIST and iRECIST criteria |
57 |
| Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease |
49 |
| Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort |
49 |
| Predictive biomarkers of response for immune checkpoint inhibitors in non-small-cell lung cancer |
43 |
| Survival and prognosis with osteosarcoma: outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort |
42 |
| Deep learning outperformed 136 of 157 dermatologists in a head-to-head dermoscopic melanoma image classification task |
41 |
| General population normative data for the EORTC QLQ-C30 health-related quality of life questionnaire based on 386 persons across 13 European countries, Canada and the Unites States |
41 |
| Anthracycline-induced cardiotoxicity: A multicenter randomised trial comparing two strategies for guiding prevention with enalapril: The International CardioOncology Society-one trial |
39 |
| Immune-related adverse events predict the therapeutic efficacy of anti-PD-1 antibodies in cancer patients |
36 |
| Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors |
34 |
| Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelines |
34 |
| A convolutional neural network trained with dermoscopic images performed on par with 145 dermatologists in a clinical melanoma image classification task |
33 |
| Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small-cell lung cancer with high tumour mutational burden: patient-reported outcomes results from the randomised, open-label, phase III CheckMate 227 trial |
32 |
| Plasma total cell-free DNA (cfDNA) is a surrogate biomarker for tumour burden and a prognostic biomarker for survival in metastatic melanoma patients |
32 |
| Trends in incidence of thick, thin and in situ melanoma in Europe |
31 |
| Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with >= 25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy |
28 |
| Detection of immune-related adverse events by medical imaging in patients treated with anti-programmed cell death 1 |
28 |
| Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial |
28 |
| Deep neural networks are superior to dermatologists in melanoma image classification |
27 |
| A systematic review of trial-level meta-analyses measuring the strength of association between surrogate end-points and overall survival in oncology |
27 |
| 2-Deoxy-2-[fluorine-18] fluoro-D-glucose uptake on positron emission tomography is associated with programmed death ligand-1 expression in patients with pulmonary adenocarcinoma |
27 |
| The impact of chemotherapy on survival of patients with extremity and trunk wall soft tissue sarcoma: revisiting the results of the EORTC-STBSG 62931 randomised trial |
27 |
| Use of nivolumab in elderly patients with advanced squamous non-small-cell lung cancer: results from the Italian cohort of an expanded access programme |
26 |
| No survival difference between robotic and open radical hysterectomy for women with early-stage cervical cancer: results from a nationwide population-based cohort study |
26 |
| Advanced cutaneous squamous cell carcinoma: A retrospective analysis of patient profiles and treatment patterns-Results of a non-interventional study of the DeCOG |
26 |
| Superior skin cancer classification by the combination of human and artificial intelligence |
25 |
| Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma |
25 |
| Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial |
25 |
| Afatinib in patients with metastatic or recurrent HER2-mutant lung cancers: a retrospective international multicentre study |
25 |
| Treatment sequencing in metastatic colorectal cancer |
24 |
| Response to salvage chemotherapy after progression on immune checkpoint inhibitors in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck |
24 |
| Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma |
24 |
| Deep learning outperformed 11 pathologists in the classification of histopathological melanoma images |
24 |
| Anti-PD-1/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B/C infection |
23 |
| No improvement in long-term survival for epithelial ovarian cancer patients: A population-based study between 1989 and 2014 in the Netherlands |
23 |
| The evolving landscape of 'next-generation' immune checkpoint inhibitors: A review |
22 |
| Evaluation of health-related quality of life and symptoms in patients with advanced non-squamous non-small cell lung cancer treated with nivolumab or docetaxel in CheckMate 057 |
22 |
| Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study: Evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer |
22 |
| The transformation of radiation oncology using real-time magnetic resonance guidance: A review |
21 |
| Buparlisib plus fulvestrant versus placebo plus fulvestrant for postmenopausal, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: Overall survival results from BELLE-2 |
21 |
| Mammography screening: A major issue in medicine |
20 |
| Metabolic crosstalk in the breast cancer microenvironment |
20 |
| Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma |
20 |
| Impact of radiation, systemic therapy and treatment sequencing on survival of patients with melanoma brain metastases |
20 |
| Systematic outperformance of 112 dermatologists in multiclass skin cancer image classification by convolutional neural networks |
19 |
| Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: long-term results of a phase III multicentre randomised controlled trial |
19 |
| NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors |
19 |
| Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study |
19 |
